Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

Questex's Fierce Life Sciences announced the agenda for the 16th annual PODD (Partnership Opportunities in Drug Delivery) Conference, scheduled for October 29-30, 2026, in Boston. The event will gather over 1,000 industry executives and features 150+ sessions with keynotes from Regeneron's Dr. George Yancopoulos and MIT's Dr. Robert Langer, covering topics including AI in drug delivery, pharma partnering strategies, and reimbursement challenges.

06/23/2026, 8:00 AM • GlobeNewswire

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.

06/22/2026, 1:00 PM • GlobeNewswire

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global GLP-1 receptor agonist market, valued at USD 28.7 billion in 2025, is projected to grow to USD 95.3 billion by 2035 at a 12.1% CAGR. Growth is driven by rising type 2 diabetes and obesity cases, technological innovations including oral formulations, and expanded insurance coverage. North America leads the market while Asia Pacific shows the highest growth rate.

06/16/2026, 6:30 PM • GlobeNewswire

This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod

AstraZeneca received FDA approval for Truqap (capivasertib) in combination with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer, marking the first targeted treatment for this patient population. The Phase III CAPItello-281 trial showed a 19% reduction in disease progression or death risk and a 7.5-month improvement in median radiographic progression-free survival. Additionally, Ultomiris received Priority Review for immunoglobulin A nephropathy treatment, with Phase 3 data showing a 46.6% reduction in proteinuria compared to 5.6% for placebo.

06/15/2026, 12:51 PM • Benzinga

AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials

AstraZeneca is advancing its oral GLP-1 receptor agonist elecoglipron into Phase 3 trials after demonstrating significant results in Phase 2b studies. The VISTA trial showed 10.5% weight reduction at 26 weeks, while the SOLSTICE trial achieved 1.9% HbA1c reduction in Type 2 diabetes patients. The drug showed a favorable safety profile with mild gastrointestinal side effects.

06/09/2026, 11:46 AM • Benzinga

MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth

MitoRx Therapeutics announces the appointment of Alison Strutt as Chief Financial Officer, László Tankó as Consultant Chief Medical Officer, and Sam Fazeli as Non-Executive Director. These appointments support the company's advancement of MTRX31, a first-in-class small molecule therapy for metabolically unhealthy obesity, towards clinical development following promising preclinical data.

06/09/2026, 7:00 AM • GlobeNewswire

AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease

AstraZeneca announced that its Phase 3 I CAN trial of Ultomiris (ravulizumab) met its primary endpoint in treating immunoglobulin A nephropathy (IgAN), showing a 46.6% reduction in proteinuria compared to 5.6% for placebo at week 34. The reduction emerged early at week 10 and was sustained through week 34, with consistent safety profile and benefits across patient subgroups.

06/08/2026, 1:02 PM • Benzinga

IEFA: Why This Fund Is One of the Best International ETFs

The iShares Core MSCI EAFE ETF (IEFA) is highlighted as one of the best international ETFs, offering diversified exposure to over 2,600 stocks across 16+ developed markets with a low 0.07% expense ratio and 3.30% dividend yield. While it has underperformed the S&P 500 recently, the fund provides valuable portfolio diversification and could serve as a hedge against U.S. market volatility, particularly if tech stocks decline from current valuations.

06/04/2026, 10:30 AM • The Motley Fool

AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study

AstraZeneca reported updated Phase 3 SERENA-6 trial results showing camizestrant combined with a CDK4/6 inhibitor delivered significant progression-free survival benefits in advanced breast cancer, reducing disease progression or death risk by 55% compared to aromatase inhibitor therapy. Median progression-free survival reached 16.8 months versus 9.2 months for the control group. The drug also showed durable benefits with 99% ctDNA reduction by week eight, though overall survival data remain immature.

06/02/2026, 2:26 PM • Benzinga

AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial

AstraZeneca announced positive Phase 3 EMERALD-3 trial results for its STRIDE immunotherapy regimen combined with lenvatinib and TACE in treating unresectable hepatocellular carcinoma. The combination achieved a 30% reduction in disease progression or death risk and median progression-free survival of 13 months versus 9.8 months with TACE alone, with an encouraging overall survival trend. However, AstraZeneca shares fell 2.69% on the news.

06/01/2026, 1:55 PM • Benzinga

Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million

Velan Capital Investment Management LP sold 140,000 shares of Mineralys Therapeutics in Q1 2026, valued at approximately $4.11 million, reducing its stake to 11,000 shares. Despite the fund's reduction, Mineralys stock has surged 87.84% over the past year. The clinical-stage biotech company is awaiting FDA approval for its lead candidate lorundrostat by December 22, 2026, and maintains $646 million in cash.

05/31/2026, 10:19 AM • The Motley Fool

ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight

The ESR1-mutated metastatic breast cancer market is projected to grow at 9.6% CAGR through 2036, driven by rising prevalence of endocrine-resistant HR-positive/HER2-negative breast cancer and adoption of precision oncology. Novel oral SERDs and targeted agents from major pharmaceutical companies are reshaping the treatment landscape. The market was valued at USD 1.5 billion in 2025, with the US representing the largest market share. Recent FDA approvals include VEPPANU (vepdegestrant), the first PROTAC therapy, while several emerging therapies are in clinical development.

05/20/2026, 1:00 PM • GlobeNewswire

Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment

The global protein synthesis research market is experiencing accelerating growth driven by increased investment in cell and gene therapy research, rising chronic disease prevalence, and expanding healthcare budgets. North America leads with 42.8% market share, while Asia-Pacific infrastructure expansion presents significant growth opportunities. Key market drivers include strong late-stage therapy pipelines and government support through initiatives like the CHIPS and Science Act.

05/18/2026, 2:33 PM • GlobeNewswire

Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight

The myasthenia gravis market is projected to grow from USD 6 billion in 2025 to over USD 16 billion by 2036, driven by rising diagnosed prevalence, improved diagnostics, and an expanding pipeline of targeted biologic therapies including FcRn inhibitors, complement inhibitors, and CAR-T cell therapies. The market is currently led by argenx and UCB, with numerous emerging candidates in late-stage development expected to significantly accelerate growth.

05/18/2026, 1:00 PM • GlobeNewswire

Studies Highlight Advances in Bladder Cancer Care and Emerging Environmental Risks

Research presented at the 2026 AUA Annual Meeting highlights progress in bladder cancer care, including findings that adding immunotherapy drug durvalumab to BCG treatment delays disease progression and helps patients avoid bladder removal surgery. Studies also reveal environmental risk factors, including air pollution and e-cigarette use, may contribute to bladder cancer development, with e-cigarette users showing earlier diagnosis ages.

05/15/2026, 2:00 PM • GlobeNewswire